Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

AXGN

Axogen Inc

Dec 12 • 04:00PM ET

30.39

+0.41 1.37 %

Healthcare • Medical Devices • USA • NASD

Peers: IART BAX SYK ZBH MDT JNJ GMED EW PODD HOLX

| Held by: IWM VTI IWO VXF IHI SCHA VTWO FESM XHE DFAS

Index	RUT	P/E	-	EPS (ttm)	-0.05	Insider Own	2.52%	Shs Outstand	46.12M	Perf Week	-8.79%
Market Cap	1.40B	Forward P/E	62.75	EPS next Y	0.48	Insider Trans	-24.47%	Shs Float	44.71M	Perf Month	26.15%
Enterprise Value	1.43B	PEG	0.78	EPS next Q	0.06	Inst Own	89.97%	Short Float	6.37%	Perf Quarter	85.64%
Income	-2.10M	P/S	6.53	EPS this Y	123.08%	Inst Trans	2.54%	Short Ratio	3.10	Perf Half Y	211.69%
Sales	214.71M	P/B	11.60	EPS next Y	67.00%	ROA	-1.03%	Short Interest	2.85M	Perf YTD	84.41%
Book/sh	2.62	P/C	35.23	EPS next 5Y	80.84%	ROE	-1.90%	52W High	34.24 -11.24%	Perf Year	104.78%
Cash/sh	0.86	P/FCF	419.66	EPS past 3/5Y	29.94% 21.24%	ROIC	-1.13%	52W Low	9.22 229.79%	Perf 3Y	186.43%
Dividend Est.	-	EV/EBITDA	126.42	Sales past 3/5Y	13.73% 11.91%	Gross Margin	74.76%	Volatility	5.84% 5.38%	Perf 5Y	74.86%
Dividend TTM	-	EV/Sales	6.66	EPS Y/Y TTM	85.77%	Oper. Margin	1.79%	ATR (14)	1.54	Perf 10Y	473.40%
Dividend Ex-Date	Jan 27, 2010	Quick Ratio	2.64	Sales Y/Y TTM	18.72%	Profit Margin	-0.98%	RSI (14)	65.58	Recom	1.10
Dividend Gr. 3/5Y	- -	Current Ratio	4.09	EPS Q/Q	134.04%	SMA20	7.51%	Beta	1.01	Target Price	36.40
Payout	-	Debt/Eq	0.56	Sales Q/Q	23.51%	SMA50	31.67%	Rel Volume	0.58	Prev Close	29.98
Employees	452	LT Debt/Eq	0.54	Earnings	Oct 29 BMO	SMA200	82.52%	Avg Volume	919.58K	Price	30.39
IPO	Dec 17, 1986	Option/Short	Yes / Yes	EPS/Sales Surpr.	66.20% 5.51%	Trades		Volume	532,642	Change	1.37%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-01-25	Initiated	Mizuho	Outperform	$40
Mar-17-25	Initiated	Lake Street	Buy	$30
Jul-01-24	Initiated	Raymond James	Outperform	$13
Nov-11-22	Resumed	Jefferies	Buy	$15
May-09-22	Upgrade	Canaccord Genuity	Hold → Buy	$10 → $15
Mar-11-22	Resumed	Cantor Fitzgerald	Overweight	$21
Oct-23-20	Initiated	Guggenheim	Buy	$24
Jun-16-20	Resumed	Cantor Fitzgerald	Overweight	$16
May-07-20	Downgrade	Canaccord Genuity	Buy → Hold	$12
Apr-02-20	Downgrade	BTIG Research	Buy → Neutral
Aug-07-19	Downgrade	William Blair	Outperform → Mkt Perform
Jul-12-19	Initiated	Canaccord Genuity	Buy	$32
Mar-02-18	Reiterated	Lake Street	Buy	$26 → $38
Jan-05-18	Resumed	Cantor Fitzgerald	Overweight
Nov-30-17	Initiated	Jefferies	Buy	$35
Nov-21-17	Reiterated	Lake Street	Buy	$22 → $26
Jul-31-17	Initiated	Leerink Partners	Outperform	$22
Jun-30-17	Initiated	Cantor Fitzgerald	Overweight	$18
Mar-06-17	Initiated	ROTH Capital	Buy	$14.50
Nov-22-16	Upgrade	Lake Street	Hold → Buy	$9 → $11

Show Previous Ratings

Dec-03-25 08:01PM	Axogen Announces FDA Approval of Biologics License Application for AVANCE (acellular nerve allograft-arwx) (GlobeNewswire) +15.97%
Nov-04-25 07:00AM	Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences (GlobeNewswire)
Oct-29-25 08:15AM	AxoGen (AXGN) Q3 Earnings and Revenues Top Estimates (Zacks) +23.06%
07:13AM	AxoGen: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Axogen, Inc. Reports Third Quarter 2025 Financial Results (GlobeNewswire)
07:00AM	Loading…
Oct-15-25 07:00AM	Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025 (GlobeNewswire)
Oct-06-25 08:04AM	CLPT Expands Into Robotic System Supporting Cell and Gene Therapies (Zacks)
Sep-26-25 09:21AM	GEHC Inks License Agreement With Lantheus for Prostate Imaging Agent (Zacks)
Sep-25-25 09:24AM	Masimo Completes Divestment of Consumer Audio Business to HARMAN (Zacks)
Sep-23-25 08:21AM	Here's Why You Should Add Inogen Stock to Your Portfolio Now (Zacks)
Sep-12-25 09:40AM	Are Medical Stocks Lagging AxoGen (AXGN) This Year? (Zacks)
Aug-28-25 09:55AM	Does AxoGen (AXGN) Have the Potential to Rally 53.1% as Wall Street Analysts Expect? (Zacks)
Aug-27-25 08:00AM	Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences (GlobeNewswire)
Aug-25-25 04:04PM	Why Axogen Stock, Up 76% Over The Last Two Months, Just Plummeted (Investor's Business Daily) -9.04% +9.60%
10:39AM	FDA Pushes Back Axogen Avance Nerve Graft Decision By 3 Months (Benzinga)
06:40AM	Loading…
06:40AM	Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft (GlobeNewswire)
Aug-20-25 09:13AM	Axogen (AXGN) Slid on a Weaker Than Expected Gross Margin (Insider Monkey)
Aug-13-25 12:08PM	Raymond James Slashes PT on Axogen (AXGN) to $20 From $21 (Insider Monkey)
Aug-12-25 09:55AM	Wall Street Analysts Predict a 76.37% Upside in AxoGen (AXGN): Here's What You Should Know (Zacks)
Aug-05-25 08:15AM	AxoGen (AXGN) Beats Q2 Earnings and Revenue Estimates (Zacks) +9.32%
07:21AM	AxoGen: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Axogen, Inc. Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-04-25 07:10AM	Waters (WAT) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
Jul-30-25 10:00AM	Will PROCEPT BioRobotics Corporation (PRCT) Report Negative Earnings Next Week? What You Should Know (Zacks)
Jul-29-25 04:10PM	Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire)
10:00AM	AxoGen (AXGN) Earnings Expected to Grow: Should You Buy? (Zacks)
Jul-22-25 04:05PM	Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025 (GlobeNewswire) +8.01% +7.34%
Jul-02-25 10:06PM	Axogen Showcases Nerve Repair Vision at Goldman Sachs (Insider Monkey)
May-28-25 08:00AM	Axogen, Inc to Participate at Goldman Sachs Global Healthcare Conference (GlobeNewswire)
May-21-25 09:35AM	AxoGen (AXGN) Loses 25.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
09:45AM	Loading…
May-09-25 09:45AM	Solventum Stock Gains on Q1 Earnings & Revenue Beat, Margins Decline (Zacks) -9.73%
09:30AM	MCK Stock Up on Q4 Earnings Beat & Potential Surgical Biz Spin-Off (Zacks)
03:08AM	Axogen Inc (AXGN) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Progress Amid ... (GuruFocus.com)
May-08-25 08:30AM	AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -23.18%
07:28AM	AxoGen: Q1 Earnings Snapshot (Associated Press Finance)
07:05AM	Axogen, Inc. Reports 2025 First Quarter Financial Results (GlobeNewswire)
07:00AM	Axogen Announces Chief Financial Officer Transition (GlobeNewswire)
May-07-25 06:00PM	Here are the major earnings before the open tomorrow (Seeking Alpha)
01:09PM	COR Q2 Earnings & Revenues Beat Estimates, '25 EPS Guidance Raised (Zacks)
12:31PM	AxoGen Q1 2025 Earnings Preview (Seeking Alpha)
May-02-25 01:22PM	SYK Stock Falls Despite Q1 Earnings & Sales Beat on Lower '25 EPS View (Zacks)
01:21PM	DexCom Stock Rises Despite Q1 Earnings Miss & Lower Margins (Zacks)
Apr-24-25 08:04AM	Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025 (GlobeNewswire)
Mar-31-25 03:03PM	Stryker Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
Mar-25-25 11:12AM	Axogen: LT Bullish, But Outcomes Weighted To Downside, At This Point (SeekingAlpha)
Mar-24-25 08:00AM	Axogen Announces Appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy, and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-04-25 03:04PM	Alcon Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
Feb-26-25 02:03AM	Axogen Inc (AXGN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Market ... (GuruFocus.com)
12:27AM	Q4 2024 AxoGen Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-25-25 07:41AM	AxoGen: Q4 Earnings Snapshot (Associated Press Finance) +11.66%
07:10AM	Axogen, Inc. To Host Analyst & Investor Day on March 4th (GlobeNewswire)
07:00AM	Axogen, Inc. Reports 2024 Fourth Quarter and Full-Year Financial Results (GlobeNewswire)
Feb-11-25 04:58PM	Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025 (GlobeNewswire)
Feb-03-25 08:00AM	Axogen Announces Appointment of Jesse Bishop as Vice President of Regulatory Affairs and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-13-25 09:35AM	AxoGen, Inc. (AXGN) Soars to 52-Week High, Time to Cash Out? (Zacks)
05:05AM	AxoGen (AXGN) Moves 18.2% Higher: Will This Strength Last? (Zacks)
Jan-10-25 05:00PM	Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +18.21%
08:00AM	Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2024 (GlobeNewswire)
Dec-24-24 09:15AM	AxoGen, Inc. (AXGN) Hits Fresh High: Is There Still Room to Run? (Zacks) -5.41%
Dec-19-24 09:40AM	Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-28-24 12:00PM	All You Need to Know About AxoGen (AXGN) Rating Upgrade to Buy (Zacks)
Nov-25-24 09:55AM	How Much Upside is Left in AxoGen (AXGN)? Wall Street Analysts Think 31.18% (Zacks)
Nov-08-24 07:35AM	AxoGen Reports Strong Q3 2024 Revenue Growth (TipRanks)
02:08AM	Axogen Inc (AXGN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements (GuruFocus.com)
Nov-07-24 07:48AM	AxoGen: Q3 Earnings Snapshot (Associated Press Finance) -13.44%
07:00AM	Axogen, Inc Reports Third Quarter 2024 Financial Results and Provides BLA Update (GlobeNewswire)
Oct-24-24 07:00AM	Axogen, Inc. to report third quarter 2024 financial results and host conference call on November 7, 2024 (GlobeNewswire)
Oct-14-24 07:21AM	AxoGen (AXGN) Surges 8.2%: Is This an Indication of Further Gains? (Zacks)
Oct-09-24 05:30PM	Axogen Inc (AXGN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ... (GuruFocus.com)
Sep-12-24 01:30AM	ArrowMark Colorado Holdings LLC Reduces Stake in Axogen Inc (GuruFocus.com)
Sep-06-24 07:00AM	Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft (GlobeNewswire)
Sep-04-24 09:15AM	AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue? (Zacks)
Sep-03-24 07:00AM	Axogen Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(C)(4) (GlobeNewswire)
Aug-30-24 12:00PM	What Makes AxoGen (AXGN) a Strong Momentum Stock: Buy Now? (Zacks)
Aug-23-24 09:55AM	Wall Street Analysts See a 25.51% Upside in AxoGen (AXGN): Can the Stock Really Move This High? (Zacks)
Aug-19-24 09:15AM	AxoGen, Inc. (AXGN) Hits Fresh High: Is There Still Room to Run? (Zacks)
Aug-13-24 04:18PM	CytoSorbents Appoints Peter J. Mariani Chief Financial Officer (GlobeNewswire)
Aug-09-24 12:56AM	Axogen names ex-Abbott exec Michael Dale as CEO (MedTech Dive)
Aug-08-24 08:20AM	AxoGen (AXGN) Q2 Earnings and Revenues Beat Estimates (Zacks) +35.10%
07:19AM	AxoGen: Q2 Earnings Snapshot (Associated Press Finance)
07:05AM	Axogen, Inc. Announces New Leadership Appointments (GlobeNewswire)
07:00AM	Axogen, Inc. Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-01-24 10:01AM	AxoGen (AXGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks) -7.06%
Jul-23-24 07:00AM	Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024 (GlobeNewswire)
Jul-12-24 08:37AM	AxoGen (AXGN) Soars 8.2%: Is Further Upside Left in the Stock? (Zacks)
Jul-01-24 07:00AM	Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) +6.49%
Jun-25-24 12:52PM	AxoGen's (AXGN) New Launch to Aid Peripheral Nerve Protection (Zacks)
Jun-24-24 07:00AM	Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix (GlobeNewswire)
Jun-12-24 04:56AM	Strength Seen in AxoGen (AXGN): Can Its 5.4% Jump Turn into More Strength? (Zacks) +9.21%
May-28-24 04:30PM	Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia (GlobeNewswire) +5.90%
May-17-24 12:29PM	AxoGen (AXGN) Initiates BLA Submission for Avance Nerve Graft (Zacks)
May-16-24 02:56PM	AxoGen Initiates Rolling Submission to FDA For Avance Nerve Graft (MT Newswires)
07:00AM	Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft (GlobeNewswire)
May-14-24 07:00AM	Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference (GlobeNewswire)
May-06-24 10:31AM	AxoGen, Inc. (NASDAQ:AXGN) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-03-24 03:02AM	Axogen Inc (AXGN) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth Amidst Challenges (GuruFocus.com)
May-02-24 11:57AM	AXGN Stock Earnings: Axogen Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) -10.37%
08:15AM	AxoGen (AXGN) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:14AM	AxoGen: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Axogen, Inc Reports First Quarter 2024 Financial Results (GlobeNewswire)

Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. The firm's products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DALE MICHAEL D	Chief Executive Officer	Dec 10 '25	Sale	30.00	25,000	750,000	63,537	Dec 12 04:06 PM
Began Marc A	EVP & General Counsel	Dec 11 '25	Sale	30.00	13,222	396,660	18,285	Dec 12 04:05 PM
MARC BEGAN	Officer	Dec 11 '25	Proposed Sale	30.00	13,222	396,660		Dec 11 04:08 PM
DALE MICHAEL D	Chief Executive Officer	Dec 09 '25	Sale	31.21	61,463	1,918,137	88,537	Dec 10 05:21 PM
TYNDALL JOSEPH A.	Director	Dec 09 '25	Option Exercise	8.73	25,108	219,223	25,108	Dec 10 05:20 PM
TYNDALL JOSEPH A.	Director	Dec 09 '25	Sale	30.98	25,108	777,771	0	Dec 10 05:20 PM
DeVinney Erick Wayne	Chief Innovation Officer	Dec 09 '25	Sale	31.21	19,517	609,087	241,132	Dec 10 05:20 PM
Kemp Jens	Chief Marketing Officer	Dec 09 '25	Sale	31.21	8,156	254,532	46,030	Dec 10 05:20 PM
Began Marc A	EVP & General Counsel	Dec 09 '25	Sale	31.21	9,278	289,548	31,507	Dec 10 05:19 PM
THOMAS PAUL	Director	Dec 09 '25	Sale	29.61	21,399	633,710	13,528	Dec 10 05:19 PM
JOHNSON JOHN	Director	Dec 08 '25	Option Exercise	6.30	11,891	74,913	25,032	Dec 10 05:19 PM
JOHNSON JOHN	Director	Dec 09 '25	Option Exercise	6.30	8,545	53,834	21,686	Dec 10 05:19 PM
JOHNSON JOHN	Director	Dec 08 '25	Sale	31.24	23,693	740,203	13,141	Dec 10 05:19 PM
JOHNSON JOHN	Director	Dec 09 '25	Sale	29.98	21,686	650,190	0	Dec 10 05:19 PM
Hartley Lindsey Marie	CFO	Dec 08 '25	Option Exercise	13.82	25,000	345,400	45,763	Dec 10 05:18 PM
Hartley Lindsey Marie	CFO	Dec 08 '25	Sale	31.56	14,387	454,005	31,376	Dec 10 05:18 PM
MICHAEL DALE	Officer	Dec 10 '25	Proposed Sale	30.00	25,000	750,000		Dec 10 04:19 PM
PAUL THOMAS	Director	Dec 09 '25	Proposed Sale	29.61	21,399	633,710		Dec 09 04:40 PM
JOSEPH A TYNDALL	Director	Dec 09 '25	Proposed Sale	30.98	25,108	777,771		Dec 09 04:39 PM
JOHN H JOHNSON	Director	Dec 09 '25	Proposed Sale	29.98	21,686	650,186		Dec 09 04:05 PM
JOHN H JOHNSON	Director	Dec 08 '25	Proposed Sale	31.24	23,693	740,207		Dec 08 06:21 PM
LINDSEY MARIE HARTLEY	Officer	Dec 08 '25	Proposed Sale	31.56	14,387	454,009		Dec 08 04:32 PM
Burke William P. Mr.	Director	Nov 10 '25	Option Exercise	8.14	19,227	156,508	19,327	Nov 13 04:31 PM
Burke William P. Mr.	Director	Nov 11 '25	Option Exercise	8.14	3,591	29,231	3,691	Nov 13 04:31 PM
Burke William P. Mr.	Director	Nov 10 '25	Sale	24.01	19,227	461,640	100	Nov 13 04:31 PM
Burke William P. Mr.	Director	Nov 11 '25	Sale	24.02	3,591	86,249	100	Nov 13 04:31 PM
WILLIAM BURKE	Director	Nov 11 '25	Proposed Sale	24.00	3,591	86,184		Nov 12 07:05 AM
WILLIAM BURKE	Director	Nov 10 '25	Proposed Sale	23.57	19,227	453,180		Nov 10 04:30 PM
Burke William P. Mr.	Director	Nov 05 '25	Option Exercise	8.14	11,431	93,048	11,531	Nov 07 04:52 PM
Burke William P. Mr.	Director	Nov 06 '25	Option Exercise	8.14	5,347	43,525	5,447	Nov 07 04:52 PM
Burke William P. Mr.	Director	Nov 05 '25	Sale	24.05	11,431	274,893	100	Nov 07 04:52 PM
Burke William P. Mr.	Director	Nov 06 '25	Sale	24.01	5,347	128,371	100	Nov 07 04:52 PM
WILLIAM BURKE	Director	Nov 06 '25	Proposed Sale	23.38	5,347	125,013		Nov 06 04:20 PM
WILLIAM BURKE	Director	Nov 05 '25	Proposed Sale	23.77	11,431	271,715		Nov 05 04:20 PM
Burke William P. Mr.	Director	Oct 29 '25	Option Exercise	7.21	40,235	289,911	20,536	Oct 31 04:09 PM
Burke William P. Mr.	Director	Oct 30 '25	Option Exercise	7.04	18,248	128,466	18,348	Oct 31 04:09 PM
Burke William P. Mr.	Director	Oct 29 '25	Sale	20.55	40,235	827,013	100	Oct 31 04:09 PM
Burke William P. Mr.	Director	Oct 30 '25	Sale	23.00	18,248	419,704	100	Oct 31 04:09 PM
WILLIAM BURKE	Director	Oct 30 '25	Proposed Sale	22.25	18,248	406,018		Oct 30 04:16 PM
WILLIAM BURKE	Director	Oct 29 '25	Proposed Sale	18.08	36,162	653,809		Oct 29 04:25 PM
Burke William P. Mr.	Director	Oct 22 '25	Sale	18.02	1,457	26,252	100	Oct 24 04:09 PM
Burke William P. Mr.	Director	Oct 22 '25	Proposed Sale	18.02	1,457	26,252		Oct 22 04:41 PM
Burke William P. Mr.	Director	Oct 06 '25	Sale	18.00	736	13,249	1,557	Oct 07 05:18 PM
Burke William P. Mr.	Director	Oct 03 '25	Sale	18.21	14,571	265,283	2,293	Oct 06 04:54 PM
Burke William P. Mr.	Director	Oct 03 '25	Sale	18.21	7,600	138,367	0	Oct 06 04:54 PM
Burke William P. Mr.	Director	Oct 02 '25	Sale	18.01	7,620	137,200	16,864	Oct 06 04:54 PM
Burke William P. Mr.	Director	Oct 02 '25	Sale	18.01	2,400	43,224	7,600	Oct 06 04:54 PM
Burke William P. Mr.	Director	Oct 06 '25	Proposed Sale	18.00	736	13,249		Oct 06 04:54 PM
WILLIAM BURKE	Director	Oct 03 '25	Proposed Sale	17.88	14,937	267,074		Oct 03 04:36 PM
Burke William P. Mr.	Director	Oct 03 '25	Proposed Sale	18.25	11,307	206,317		Oct 03 04:29 PM
Burke William P. Mr.	Director	Oct 02 '25	Proposed Sale	18.01	2,400	43,224		Oct 02 04:24 PM
WILLIAM BURKE	Director	Oct 02 '25	Proposed Sale	17.87	7,620	136,169		Oct 02 04:21 PM
DeVinney Erick Wayne	Chief Innovation Officer	Sep 16 '25	Sale	16.29	1,137	18,522	220,649	Sep 16 05:22 PM
Weiler Kathy Johnson	Director	Jun 09 '25	Sale	10.61	4,073	43,215	6,580	Jun 11 04:27 PM
Levine Alan M	Director	Jun 09 '25	Sale	10.61	4,073	43,215	36,743	Jun 11 04:26 PM
Wendell Amy McBride	Director	Jun 09 '25	Sale	10.61	4,073	43,215	93,826	Jun 11 04:26 PM
Burke William P. Mr.	Director	Jun 09 '25	Sale	10.61	4,073	43,215	24,484	Jun 11 04:25 PM
NEELS GUIDO J	Director	Jun 09 '25	Sale	10.61	4,073	43,215	86,743	Jun 11 04:24 PM
JOHNSON JOHN	Director	Jun 09 '25	Sale	10.61	4,073	43,215	24,943	Jun 11 04:23 PM
TYNDALL JOSEPH A.	Director	Jun 10 '25	Option Exercise	6.56	11,586	75,952	26,931	Jun 11 04:22 PM
TYNDALL JOSEPH A.	Director	Jun 10 '25	Sale	10.72	26,931	288,700	0	Jun 11 04:22 PM
JOSEPH A TYNDALL	Director	Jun 10 '25	Proposed Sale	10.72	26,931	288,814		Jun 10 05:41 PM
TYNDALL JOSEPH A.	Director	May 22 '25	Option Exercise	6.30	12,850	80,955	35,407	May 23 04:32 PM
TYNDALL JOSEPH A.	Director	May 22 '25	Sale	11.20	20,062	224,694	15,345	May 23 04:32 PM
TYNDALL JOSEPH A.	Director	May 19 '25	Sale	11.63	2,525	29,366	22,557	May 23 04:12 PM
TYNDALL JOSEPH A.	Director	May 22 '25	Proposed Sale	11.15	32,339	360,580		May 22 05:14 PM
DeVinney Erick Wayne	Chief Innovation Officer	Mar 16 '25	Option Exercise	0.00	32,462	0	232,873	Mar 19 05:24 PM
DeVinney Erick Wayne	Chief Innovation Officer	Mar 19 '25	Sale	17.50	15,111	264,442	217,762	Mar 19 05:24 PM
Began Marc A	EVP & General Counsel	Mar 01 '25	Option Exercise	0.00	22,500	0	24,186	Mar 05 06:24 PM
Wendell Amy McBride	Director	Mar 03 '25	Sale	20.02	5,000	100,100	97,899	Mar 05 06:20 PM
DeVinney Erick Wayne	Chief Innovation Officer	Feb 28 '25	Option Exercise	0.00	24,799	0	209,301	Mar 04 07:22 PM
AMY MCBRIDE-WENDELL	Director	Mar 03 '25	Proposed Sale	20.01	5,000	100,050		Mar 03 04:16 PM
Kemp Jens	Chief Marketing Officer	Feb 22 '25	Option Exercise	0.00	2,500	0	2,500	Feb 26 04:25 PM
Zaderej Karen L.	SENIOR ADVISOR	Jan 21 '25	Proposed Sale	18.41	220,000	4,050,000		Jan 21 01:20 PM
Zaderej Karen L.	SENIOR ADVISOR	Jan 14 '25	Proposed Sale	18.00	100,000	1,800,000		Jan 14 01:24 PM

Open in Screener

XERS

Xeris Biopharma Holdings Inc

Dec 12 • 04:00PM ET

7.17

+0.16 2.28 %

Healthcare • Biotechnology • USA • NASD

XERS Xeris Biopharma Holdings Inc daily Stock Chart

Peers: LGND ALKS BCRX SUPN AMRN ANIP MNKD RDHL ECOR

| Held by: VTI IWM VXF IWO VTWO SCHA VHT XPH IWC DWAS

Index	RUT	P/E	-	EPS (ttm)	-0.10	Insider Own	6.79%	Shs Outstand	165.53M	Perf Week	10.14%
Market Cap	1.19B	Forward P/E	39.75	EPS next Y	0.18	Insider Trans	-2.08%	Shs Float	154.96M	Perf Month	-5.53%
Enterprise Value	1.36B	PEG	-	EPS next Q	0.02	Inst Own	58.99%	Short Float	10.31%	Perf Quarter	-2.58%
Income	-15.64M	P/S	4.47	EPS this Y	92.68%	Inst Trans	4.64%	Short Ratio	6.52	Perf Half Y	64.83%
Sales	266.14M	P/B	-	EPS next Y	765.94%	ROA	-4.52%	Short Interest	15.97M	Perf YTD	111.50%
Book/sh	-0.01	P/C	12.99	EPS next 5Y	-	ROE	-	52W High	10.08 -28.87%	Perf Year	100.28%
Cash/sh	0.55	P/FCF	119.33	EPS past 3/5Y	37.81% 40.01%	ROIC	-6.24%	52W Low	3.14 128.34%	Perf 3Y	404.93%
Dividend Est.	-	EV/EBITDA	60.44	Sales past 3/5Y	59.99% 136.89%	Gross Margin	80.48%	Volatility	4.73% 4.50%	Perf 5Y	72.36%
Dividend TTM	-	EV/Sales	5.09	EPS Y/Y TTM	76.50%	Oper. Margin	3.68%	ATR (14)	0.36	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.35	Sales Y/Y TTM	42.05%	Profit Margin	-5.88%	RSI (14)	47.39	Recom	1.43
Dividend Gr. 3/5Y	- -	Current Ratio	1.93	EPS Q/Q	103.31%	SMA20	2.95%	Beta	0.65	Target Price	11.14
Payout	-	Debt/Eq	-	Sales Q/Q	37.06%	SMA50	-10.42%	Rel Volume	0.63	Prev Close	7.01
Employees	394	LT Debt/Eq	-	Earnings	Nov 06 BMO	SMA200	16.28%	Avg Volume	2.45M	Price	7.17
IPO	Jun 21, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-100.00% -0.17%	Trades		Volume	1,534,477	Change	2.28%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-09-25	Initiated	Barclays	Overweight	$9
Aug-12-25	Resumed	H.C. Wainwright	Buy	$10
Nov-11-24	Downgrade	Piper Sandler	Overweight → Neutral	$3
Mar-28-24	Initiated	Oppenheimer	Outperform	$5
Aug-28-23	Initiated	Craig Hallum	Buy	$4.50
Oct-21-22	Initiated	Jefferies	Buy	$4
Apr-28-22	Initiated	Craig Hallum	Buy	$6.50
Nov-17-21	Initiated	SVB Leerink	Outperform	$6
Oct-29-21	Initiated	H.C. Wainwright	Buy	$4
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$11
Feb-18-20	Initiated	Piper Sandler	Overweight	$12
Jul-16-18	Initiated	RBC Capital Mkts	Outperform	$24
Jul-16-18	Initiated	Leerink Partners	Outperform	$24
Jul-16-18	Initiated	Jefferies	Buy	$23

Show Previous Ratings

Dec-01-25 07:00AM	Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application (Business Wire)
Nov-06-25 09:30AM	Xeris Biopharma (XERS) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks) -21.88%
08:30AM	Xeris Biopharma (XERS) Reports Break-Even Earnings for Q3 (Zacks)
07:00AM	Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025 (Business Wire)
Oct-30-25 06:45PM	Plus Therapeutics (PSTV) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Loading…
Oct-23-25 07:30AM	Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025 (Business Wire)
Oct-20-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Xeris Biopharma (XERS) is a Great Choice (Zacks)
09:15AM	Xeris Biopharma Holdings, Inc. (XERS) Hit a 52 Week High, Can the Run Continue? (Zacks)
Oct-16-25 09:06AM	Xeris Biopharma (XERS) Surges 14.2%: Is This an Indication of Further Gains? (Zacks)
Oct-13-25 07:58AM	Beat the Market the Zacks Way: MariMed, Xeris Biopharma, Lam Research in Focus (Zacks)
Oct-03-25 04:15PM	Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
12:00PM	Xeris Biopharma (XERS) is a Great Momentum Stock: Should You Buy? (Zacks)
09:15AM	Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run? (Zacks)
Sep-09-25 12:00PM	What Makes Xeris Biopharma (XERS) a Strong Momentum Stock: Buy Now? (Zacks)
Aug-29-25 05:09AM	Xeris Biopharma Holdings, Inc. (XERS) Reports Record $71.5M Q2 Revenue (Insider Monkey)
07:00AM	Loading…
Aug-25-25 07:00AM	Xeris Announces Orange Book Listing of U.S. Patent for Recorlev (Business Wire)
Aug-12-25 12:00PM	Xeris Biopharma (XERS) Upgraded to Buy: Here's Why (Zacks)
09:15AM	Xeris Biopharma Holdings, Inc. (XERS) Hits Fresh High: Is There Still Room to Run? (Zacks)
Aug-07-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +20.22%
09:30AM	Xeris Biopharma (XERS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:35AM	Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:32AM	Xeris Biopharma: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance (Business Wire)
Jul-31-25 07:30AM	Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025 (Business Wire)
Jul-03-25 08:19AM	Zevra Therapeutics (ZVRA) Moves 5.1% Higher: Will This Strength Last? (Zacks)
Jun-03-25 07:30AM	Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day (Business Wire) -7.92%
May-20-25 07:30AM	Xeris Announces Details for Analyst & Investor Day (Business Wire)
May-12-25 03:54PM	Xeris Biopharma Holdings, Inc. (XERS): Among the Unstoppable Growth Stocks to Invest in Now (Insider Monkey)
May-09-25 03:21AM	Xeris Biopharma Holdings Inc (XERS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
May-08-25 08:20AM	Xeris Biopharma (XERS) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +15.18%
07:17AM	Loading…
07:17AM	Xeris Biopharma: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Reports Record First Quarter 2025 Financial Results (Business Wire)
May-07-25 12:08PM	Xeris Pharmaceuticals Q1 2025 Earnings Preview (Seeking Alpha)
11:51AM	Xeris Biopharma Holdings: Looking For More Growth In Q1 Earnings (Seeking Alpha)
May-05-25 05:30PM	Corcept Therapeutics (CORT) Meets Q1 Earnings Estimates (Zacks) -7.33%
May-01-25 07:00AM	Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025 (Business Wire)
Apr-22-25 06:46PM	Is Xeris Biopharma Holdings Inc. (XERS) the Best Multibagger Penny Stock to Buy According to Billionaires? (Insider Monkey)
Apr-17-25 07:00AM	Bright Peak Therapeutics Appoints John Schmid to its Board of Directors (GlobeNewswire)
Mar-28-25 08:00AM	Xeris Announces Changes to Its Board of Directors (Business Wire)
Mar-27-25 10:18AM	Is Xeris Biopharma Holdings (XERS) The Hot Biotech Stock Under $5? (InsiderMonkey)
Mar-20-25 10:13AM	Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength? (Zacks)
Mar-19-25 04:49PM	Xeris Biopharma Holdings (XERS): Among the Best Stocks to Invest in for a Stock Market Game (InsiderMonkey) +5.56%
Mar-17-25 08:00AM	Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx (glucagon) for Use as a Diagnostic Aid (Business Wire)
Mar-07-25 02:08AM	Xeris Biopharma Holdings Inc (XERS) Q4 2024 Earnings Call Highlights: Surpassing Revenue ... (GuruFocus.com)
Mar-06-25 09:30AM	Here's What Key Metrics Tell Us About Xeris Biopharma (XERS) Q4 Earnings (Zacks) +9.55%
08:15AM	Xeris Biopharma (XERS) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:22AM	Xeris Biopharma: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Delivers Record Fourth Quarter and Full-Year 2024 Results; and Announces 2025 Guidance (Business Wire)
Feb-27-25 07:00AM	Xeris Biopharma to Report Fourth Quarter and Full-Year 2024 Financial Results on March 6, 2025 (Business Wire)
Feb-26-25 10:00AM	Xeris Biopharma (XERS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-24-25 08:00AM	Xeris Appoints Anh Nguyen, MD, MBA as Chief Medical Officer (Business Wire)
Feb-05-25 08:00AM	Xeris to Participate in Upcoming Investor Conferences (Business Wire)
Jan-21-25 09:00AM	The American Diabetes Association and Xeris Pharmaceuticals Announce National Collaboration to Provide Life-Saving Hypoglycemia Education and Awareness (PR Newswire)
Jan-11-25 07:27AM	Xeris Biopharma raises FY24 revenue view to $203M from $198M-$202M (TipRanks)
Jan-10-25 07:00AM	Xeris Expects to Exceed Full-Year 2024 Financial Guidance (Business Wire)
Jan-06-25 04:15PM	Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -5.37%
Nov-26-24 07:00AM	Xeris to Participate in Piper Sandler 36th Annual Healthcare Conference (Business Wire)
Nov-09-24 02:06AM	Xeris Biopharma Holdings Inc (XERS) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Nov-08-24 09:30AM	Xeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:10AM	Xeris Biopharma (XERS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:10AM	Xeris Biopharma: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Reports Third Quarter 2024 Financial Results (Business Wire)
Oct-31-24 08:00AM	Xeris Biopharma to Report Third Quarter 2024 Financial Results on November 8, 2024 (Business Wire)
Oct-04-24 04:05PM	Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Aug-22-24 07:00AM	Xeris to Participate in Upcoming Investor Conferences (Business Wire)
Aug-08-24 08:25AM	Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Xeris Biopharma: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Reports Second Quarter 2024 Financial Results (Business Wire)
Aug-01-24 10:01AM	Will Xeris Biopharma (XERS) Report Negative Earnings Next Week? What You Should Know (Zacks)
Jul-25-24 07:00AM	Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024 (Business Wire) +6.02%
Jul-24-24 09:55AM	Xeris Biopharma (XERS) Now Trades Above Golden Cross: Time to Buy? (Zacks) -5.12%
Jul-08-24 07:00AM	Xeris Biopharma Announces CEO Succession Plan (Business Wire)
Jul-03-24 01:05PM	Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jun-03-24 07:00AM	Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev) in Cushings Syndrome Patients at ENDO 2024 (Business Wire) +8.65%
May-30-24 07:30AM	Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121) (Business Wire) +15.03%
07:00AM	Xeris to Participate in the Jefferies Global Healthcare Conference (Business Wire)
May-10-24 03:21PM	Xeris Biopharma Holdings Inc (XERS) Q1 2024 Earnings: Revenue Growth Amidst Challenges (GuruFocus.com) -6.38%
12:36PM	Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2024 Earnings Call Transcript (Insider Monkey)
12:27AM	Q1 2024 Xeris Biopharma Holdings Inc Earnings Call (Thomson Reuters StreetEvents)
May-09-24 11:55AM	XERS Stock Earnings: Xeris Biopharma Holdings Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:10AM	Xeris Biopharma (XERS) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:11AM	Xeris Biopharma: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events (Business Wire)
May-06-24 07:42AM	Xeris Biopharma Collaborating With Beta Bionics for Development, Commercialization of Glucagon Product (MT Newswires)
07:00AM	Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics (Business Wire)
May-02-24 07:00AM	Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024 (Business Wire) +6.29%
Apr-03-24 04:05PM	Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Apr-02-24 07:00AM	Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-07-24 01:47PM	Xeris Biopharma Holdings Inc (XERS) Reports Robust Revenue Growth in Q4 and Full Year 2023 (GuruFocus.com)
11:56AM	Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-06-24 11:16PM	Q4 2023 Xeris Biopharma Holdings Inc Earnings Call (Thomson Reuters StreetEvents) -19.48%
12:52PM	XERS Stock Earnings: Xeris Biopharma Holdings Meets EPS, Beats Revenue for Q4 2023 (InvestorPlace)
08:15AM	Xeris Biopharma (XERS) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:17AM	Xeris Biopharma: Q4 Earnings Snapshot (Associated Press Finance)
07:02AM	Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events (Business Wire)
07:00AM	Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital (Business Wire)
Mar-05-24 09:42AM	Why Xeris (XERS) Might Surprise This Earnings Season (Zacks)
Feb-28-24 07:00AM	Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024 (Business Wire)
Feb-05-24 07:00AM	Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference (Business Wire)
Jan-11-24 08:30AM	Xeris (XERS) Up on Licensing Deal With Amgen to Develop Tepezza (Zacks)

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BARBARA-JEAN A BORMANN-KENNEDY	Director	Dec 12 '25	Proposed Sale	7.01	15,000	105,150		Dec 12 04:20 PM
Hecht Beth	See Remarks	Dec 01 '25	Sale	7.01	16,667	116,781	1,320,176	Dec 02 05:14 PM
Shannon John Patrick Jr	See Remarks	Nov 14 '25	Option Exercise	1.55	87,100	135,005	2,730,253	Nov 17 05:58 PM
Shannon John Patrick Jr	See Remarks	Nov 13 '25	Option Exercise	1.55	8,970	13,904	2,666,395	Nov 17 05:58 PM
Shannon John Patrick Jr	See Remarks	Nov 13 '25	Sale	7.46	23,242	173,402	2,643,153	Nov 17 05:58 PM
Hecht Beth	See Remarks	Nov 11 '25	Sale	7.40	16,667	123,296	1,336,843	Nov 13 06:59 PM
JOHN SHANNON	Director	Nov 13 '25	Proposed Sale	7.59	48,149	365,451		Nov 13 04:25 PM
BETH HECHT	Officer	Nov 11 '25	Proposed Sale	7.72	66,668	514,677		Nov 12 07:02 AM
PERSKY MARLA	Director	Sep 11 '25	Sale	7.72	15,500	119,610	142,000	Sep 12 05:09 PM
MARLA PERSKY	Director	Sep 11 '25	Proposed Sale	7.81	15,500	121,055		Sep 11 04:24 PM
SHERMAN JEFFREY W	Director	Aug 28 '25	Option Exercise	6.66	47,040	313,286	261,420	Aug 29 05:21 PM
SHERMAN JEFFREY W	Director	Aug 28 '25	Sale	7.92	42,232	334,515	219,188	Aug 29 05:21 PM
JEFFREY SHERMAN	Director	Aug 28 '25	Proposed Sale	7.92	42,232	334,511		Aug 28 04:09 PM
JOHNSON JOHN	Director	Aug 13 '25	Sale	7.32	107,500	786,459	833,483	Aug 15 04:57 PM
HALKUFF DAWN	Director	Aug 12 '25	Sale	7.28	42,500	309,226	115,000	Aug 13 04:47 PM
JOHN H JOHNSON	Director	Aug 13 '25	Proposed Sale	7.32	107,500	786,452		Aug 13 04:08 PM
DAWN HALKUFF	Director	Aug 12 '25	Proposed Sale	7.28	42,500	309,226		Aug 12 04:23 PM
McCulloch Kevin	See Remarks	Jun 13 '25	Buy	4.38	25,000	109,475	1,708,585	Jun 16 04:26 PM
Fairley Ricki Louise	Director	May 09 '25	Proposed Sale	4.90	56,667	277,668		May 09 05:28 PM
Hecht Beth	See Remarks	Mar 20 '25	Sale	5.43	40,000	217,244	1,353,510	Mar 21 05:31 PM
Hecht Beth	Officer	Mar 20 '25	Proposed Sale	5.14	40,000	205,600		Mar 20 05:26 PM

AXGN

Axogen Inc

XERS

Xeris Biopharma Holdings Inc

Upgrade your FINVIZ experience